PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15349044

Developments in ocular allergy.

Shayla L Chambless·Stefan Trocme
View original source ↗Export metadata ↓

Abstract

PURPOSE OF REVIEW: The goal of this article is to evaluate developments in the knowledge of inflammatory mechanisms and treatments of ocular allergy. RECENT FINDINGS: Research developments in ocular allergy summarized in this article include the following findings: (1) ocular epithelial cells play a role in inflammation; (2) respiratory syncytial virus is a pathogen in allergic conjunctivitis; (3) transglutaminase inhibitors reverse allergic related inflammation; (4) eosinophils and neutrophils both play a role in ocular allergy; (5) eotaxin-1 and eotaxin-2 play a role in eosinophilic recruitment; and (6) loteprednol etabonate, desonide phosphate, and cyclosporine have been shown to be effective and safe in the treatment of ocular allergy. SUMMARY: This article summarizes the research conducted for each of the above recent findings and outlines their clinical applications.

Explore related subjects

Administration, TopicalAnti-Inflammatory AgentsConjunctivitis, AllergicHumansKeratoconjunctivitisTreatment OutcomeJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Shayla L Chambless, Stefan Trocme. 2004. Developments in ocular allergy.. https://doi.org/10.1097/00130832-200410000-00016

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Pharmacokinetics of timolol in aqueous humor sampled by microdialysis after topical administration of thermosetting gels.

In order to develop a thermosetting gel-based formulation, the ocular pharmacokinetics of timolol was studied utilizing microdialysis sampling technique after topical administration. A linear microdialysis probe was characterized and implanted in the anterior chamber of a rabbit. Dialysate samples collected from the aqueous humor (AH) were directly injected into the HPLC system without any pre-treatment and no interference was observed in the blank sample. The measured in vitro recovery of the probe was 57.67%; however, the in vivo recovery significantly decreased to 16.78% when assessed by the retrodialysis method, which was used to calculate the timolol concentration in AH. Although in the initial 15 min the drug concentrations in AH were comparable to that of the timolol solution, increased Cmax and significantly improved ocular bioavailability were obtained for the gel. When sodium deoxycholate (DC) was incorporated in the gel as a penetration enhancer, a 2-fold increment in the ocular bioavailability was achieved with an increased Cmax and significantly suspended Tmax. The results demonstrated that microdialysis coupled to HPLC is a powerful tool to investigate the ocular pharmacokinetic, and hence facilitates the design of ophthalmic formulations.

Administration, Topical↗
PubMed2006

[Treatment of paraungual HPV73-positive Bowen disease with imiquimod cream].

Bowen disease - a squamous cell carcinoma in situ - is associated with oncogenic human papilloma viruses (HPV). The association is best established for genital Bowen disease but also holds for extragenital lesions. The immunomodulatory substance imiquimod is used for the treatment of HPV-induced skin disorders. In the case of paraungual Bowen disease, established treatment options as excision, cryosurgery, radiotherapy or laser treatment might cause persistent nail damage. We successfully treated HPV73-positive Bowen disease in this location with topical imiquimod.

Administration, Topical↗
PubMed2006

[Adjuvant topical interferon-alpha-2b treatment in epithelial tumors of the ocular surface].

PURPOSE: The aim of this study was to evaluate the role of topical interferon-alpha-2b in the adjuvant treatment of corneal and conjunctival tumors. METHOD: In this noncomparative, prospective, interventional case series, five patients with histologically proven conjunctival intraepithelial neoplasia (CIN) after primary excision and amniotic membrane transplantation were treated with interferon (IFN)-alpha-2b eye drops five times daily over a period of 6 weeks (1 million IU/ml Intron A, Schering). An in situ hybridization technique was used to detect human papillomavirus (HPV) in all specimens. Frequent follow-up was undertaken clinically and photographically for evidence of tumor recurrence. RESULTS: In the follow-up period (13.2+/-4,97 months) no clinical evidence of recurrence with only limited treatment side effects such as mild conjunctival hyperemia were recorded after 6 weeks of interferon. In one CIN specimen HPV 16/18 could be detected. CONCLUSIONS: The combination of excisional biopsy and topical interferon-alpha-2b application seems to be an effective and safe treatment for conjunctival intraepithelial neoplasias. Therefore, we prefer this combined treatment to topical interferon-alpha-2b treatment alone, more destructive approaches such as radiation and cryotherapy, or treatment with antimetabolites such as 5-fluorouracil or mitomycin C.

Administration, Topical↗